Diurnal Group PLC (DNL) Insider John Goddard Acquires 10,791 Shares
Diurnal Group PLC (LON:DNL) insider John Goddard purchased 10,791 shares of the company’s stock in a transaction dated Thursday, September 7th. The stock was purchased at an average price of GBX 5 ($0.06) per share, for a total transaction of £539.55 ($696.82).
Diurnal Group PLC (LON DNL) opened at 133.50 on Friday. The stock has a 50 day moving average of GBX 132.07 and a 200-day moving average of GBX 130.20. The firm’s market cap is GBX 69.70 million. Diurnal Group PLC has a 12 month low of GBX 105.00 and a 12 month high of GBX 143.50.
WARNING: This piece of content was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/09/09/diurnal-group-plc-dnl-insider-john-goddard-acquires-10791-shares.html.
A number of brokerages have recently issued reports on DNL. Numis Securities Ltd restated a “buy” rating and issued a GBX 169 ($2.18) price target on shares of Diurnal Group PLC in a research report on Wednesday. Panmure Gordon restated a “buy” rating and issued a GBX 178 ($2.30) price target on shares of Diurnal Group PLC in a research report on Thursday, June 15th.
Diurnal Group PLC Company Profile
Diurnal Group plc is a clinical-stage pharmaceutical company. The Company is engaged in developing hormone therapeutics to aid treatment for various endocrine conditions. The Company’s products include Chronocort, which is engaged in developing hydrocortisone product for the treatment of congenital adrenal hyperplasia and adrenal insufficiency; Infacort, which is engaged in creating paediatric hydrocortisone replacement product for neonates and infants suffering from adrenal insufficiency; Native Oral Testosterone, which is engaged in creating oral testosterone treatment for hypogonadism, and Tri4Combi, which is engaged in developing combination therapy product of thyroid hormones for patients suffering from hypothyroidism.
Receive News & Stock Ratings for Diurnal Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diurnal Group PLC and related stocks with our FREE daily email newsletter.